Role of adalimumab in the treatment of early rheumatoid arthritis. Academic Article Article uri icon

Overview

MeSH

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Subcutaneous
  • Male
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

MeSH Major

  • Antibodies, Monoclonal
  • Arthritis, Rheumatoid

abstract

  • Adalimumab, a recent addition to the therapeutic armamentarium in rheumatoid arthritis (RA), has been evaluated in patients with early RA. The DE019 study, a double blind randomized placebo controlled trial of adalimumab given 20 mg once a week or 40 mg every other week demonstrated both clinical and radiographic efficacy. A subset analysis of patients with early disease revealed that early treatment with adalimumab may be more efficacious than therapy later in the course of disease, particularly with regard to radiographic progression. The findings support early aggressive intervention in RA.

publication date

  • October 2003
  • September 2003

has subject area

  • Adalimumab
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Subcutaneous
  • Male
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Research

keywords

  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Randomized Controlled Trial

Identity

Language

  • eng

PubMed ID

  • 14969077

Additional Document Info

start page

  • S198

end page

  • S199

volume

  • 21

number

  • 5 Suppl 31